Cell and Gene Therapy Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	247 Pages	Coherent Market Insights	July, 2023	CMI18163334

Best Price Guarantee
Price	from $4,500
Length	247 Pages
Publisher	Coherent Market Insights
Published Date	July, 2023
SKU	CMI18163334

Cell and Gene Therapy Market, By Therapy Type, By Application, By End User, By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Cell therapy is the introduction of new cells into a patient’s body to grow, replace, or repair damaged tissue in order to treat a disease. A variety of different types of cells can be used in cell therapy, including stem cells, lymphocytes, and dendritic cells. Cell therapies can use cells from the patient’s own body (autologous) or from a donor (allogenic). Many cell therapies use adult cells that have been genetically reprogrammed and capable of becoming one of many types of cells inside a patient’s body. This technology may enable the development of unlimited types of specific human cells needed for therapeutic purposes.

Gene therapy seeks to modify or introduce genes into a patient’s body with the goal of treating, preventing, or potentially curing a disease. Examples of gene therapy approaches include replacing a mutated gene that causes disease with a functional copy or introducing a new, correct copy of a gene into the body.

Market Dynamics

Cell and gene therapy plays a major role in modern healthcare, as it provides concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling. Thus, key market players are focused on adopting various growth strategies such as product/platform launches and others, which in turn is expected to fuel the market growth over the forecast period. For instance, on April 4, 2023, AmerisourceBergen, a global healthcare company, announced the launch of its Cell and Gene Therapy (CGT) Integration Hub, a system that can be integrated with biopharma or provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the treatment development and patient journey.

Furthermore, The CGT Integration Hub, which is platform-agnostic and powered by AmerisourceBergen’s innovative customer relationship management (CRM) system, aims to streamline the path-to-care process, in part, by providing physicians and patient services teams with enhanced visibility across the therapy development and delivery process. Through platform integrations, the CGT Integration Hub can:

Speed up the benefits investigation process so that after physicians enter patient enrollment data, they can get a decision on the patient's coverage almost immediately.
To facilitate patient scheduling, give doctors and care managers real-time access to information on the status of the development of the therapy and transportation.
Inform case managers of any status changes, such as postponed arrival dates, so they can contact patients and caregivers in advance to amend any scheduled treatment-related activities or stays, as necessary.

Key features of the study:

This report provides an in-depth analysis of the global cell and gene therapy market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cell and gene therapy market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., Bluebird Bio, Inc. (Celgene Corporation) , Biogen Inc., uniQure N.V., JCR Pharmaceuticals Co. Ltd., Gene Biotherapeutics, Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Organogenesis, Inc., Orchard Therapeutics Plc., Freeline Therapeutics Ltd. , Bristol-Myers Squibb Company, PTC Therapeutics, Inc., Spark Therapeutics, Inc. and Biomarin Pharmaceutical Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell and gene therapy market

Detailed Segmentation:

Global Cell and Gene Therapy Market, By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Gene Therapy
Germline Gene Therapy
Somatic Gene Therapy
Global Cell and Gene Therapy Market, By Application:
Dermatology
Musculoskeletal
Oncology
Immunology
Cardiology & Neurology
Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
Global Cell and Gene Therapy Market, By End user:
Hospitals
Clinics
Others (Research Institutes, Academic Institutes, etc.)
Global Cell and Gene Therapy Market, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
Novartis International AG
Pfizer, Inc.
Sanofi S.A.
Amgen, Inc.
Regeneron Pharmaceuticals, Inc.
Bluebird Bio, Inc. (Celgene Corporation)
Biogen Inc.
uniQure N.V.
JCR Pharmaceuticals Co. Ltd.
Gene Biotherapeutics
Kolon TissueGene, Inc.
Horama S.A.
MeiraGTx Limited
Gilead Sciences, Inc.
Organogenesis, Inc.
Orchard Therapeutics Plc.
Freeline Therapeutics Ltd.
Bristol-Myers Squibb Company
PTC Therapeutics, Inc.
Spark Therapeutics, Inc.
Biomarin Pharmaceutical Inc.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Therapy Type; Market Snapshot, By Application; Market Snapshot, By End user; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Merger, Acquisition, and Collaborations; Regulatory Scenario; Key Developments; PEST Analysis; Technological Advancements; Manufacturer Revenue; Pipeline Analysis
4. Global Cell and Gene Therapy Market – COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Cell and Gene Therapy Market, By Therapy Type, 2018 – 2030, (US$ Billion): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Cell Therapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion); Segment Trends; Stem Cells; T Cells; Dendritic Cells; NK Cells; Gene Therapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion); Segment Trends; Germline Gene Therapy; Somatic Gene Therapy
6. Global Cell and Gene Therapy Market, By Application, 2018 – 2030, (US$ Billion): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Dermatology; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion); Segment Trends; Musculoskeletal; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion); Segment Trends; Oncology; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion); Segment Trends; Immunology; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion); Segment Trends; Cardiology & Neurology; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion); Segment Trends; Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion); Segment Trends
7. Global Cell and Gene Therapy Market, By End user, 2018 – 2030, (US$ Billion): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Hospitals; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion); Clinics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion); Others (Research Institutes, Academic Institutes, etc.); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Billion)
8. Global Cell and Gene Therapy Market, By Region, 2018 – 2030, (US$ Billion): Introduction; Market Share Analysis, By Region, 2023 and 2030 (%); Y-o-Y Growth Analysis, For Regions, 2018–2030; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 – 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 – 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 – 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 – 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 – 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 – 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion); North Africa; Central Africa; South Africa
9. Competitive Landscape: Novartis International AG*; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Pfizer, Inc.; Sanofi S.A.; Amgen, Inc.; Regeneron Pharmaceuticals, Inc.; Bluebird Bio, Inc. (Celgene Corporation); Biogen Inc.; uniQure N.V.; JCR Pharmaceuticals Co. Ltd.; Gene Biotherapeutics; Kolon TissueGene, Inc.; Horama S.A.; MeiraGTx Limited; Gilead Sciences, Inc.; Organogenesis, Inc.; Orchard Therapeutics Plc.; Freeline Therapeutics Ltd.; Bristol-Myers Squibb Company; PTC Therapeutics, Inc.; Spark Therapeutics, Inc.; Biomarin Pharmaceutical Inc.
10. Section: Research Methodology; About Us; *Browse 45 market data tables and 36 figures on “Cell and Gene Therapy Market” Global forecast to 2030